Rafferty Asset Management
SNDX icon

Rafferty Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Rafferty Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Sell
97,787
-26,936
-22% -$560K ﹤0.01% 627
2026
Q1 		$2.91M Sell
124,723
-37,220
-23% -$809K 0.01% 520
2025
Q4 		$3.4M Buy
161,943
+20,121
+14% +$351K 0.01% 530
2025
Q3 		$2.18M Buy
141,822
+15,777
+13% +$207K 0.01% 631
2025
Q2 		$1.18M Sell
126,045
-45,496
-27% -$501K ﹤0.01% 732
2025
Q1 		$2.11M Sell
171,541
-6,624
-4% -$93.4K 0.01% 568
2024
Q4 		$2.36M Buy
178,165
+6,643
+4% +$114K 0.01% 599
2024
Q3 		$3.3M Sell
171,522
-6,398
-4% -$132K 0.01% 511
2024
Q2 		$3.65M Sell
177,920
-195,318
-52% -$4.09M 0.01% 483
2024
Q1 		$8.88M Sell
373,238
-30,143
-7% -$672K 0.03% 310
2023
Q4 		$8.72M Buy
403,381
+119,257
+42% +$1.83M 0.04% 316
2023
Q3 		$4.13M Sell
284,124
-51,223
-15% -$969K 0.02% 435
2023
Q2 		$7.02M Buy
335,347
+52,464
+19% +$1.09M 0.04% 340
2023
Q1 		$5.97M Buy
282,883
+18,121
+7% +$451K 0.04% 342
2022
Q4 		$6.74M Buy
264,762
+118,380
+81% +$2.76M 0.06% 310
2022
Q3 		$3.52M Buy
146,382
+68,478
+88% +$1.54M 0.04% 390
2022
Q2 		$1.5M Sell
77,904
-52,575
-40% -$876K 0.01% 539
2022
Q1 		$2.27M Sell
130,479
-27,353
-17% -$461K 0.01% 567
2021
Q4 		$3.46M Buy
157,832
+84,100
+114% +$1.55M 0.02% 506
2021
Q3 		$1.41M Sell
73,732
-64,440
-47% -$1.07M 0.01% 729
2021
Q2 		$2.37M Sell
138,172
-7,269
-5% -$133K 0.01% 632
2021
Q1 		$3.25M Buy
145,441
+127,618
+716% +$2.88M 0.02% 434
2020
Q4 		$396K Sell
17,823
-8,573
-32% -$178K ﹤0.01% 738
2020
Q3 		$390K Buy
+26,396
New +$402K ﹤0.01% 745

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Rafferty Asset Management's SNDX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Syndax Pharmaceuticals (SNDX) stake by 22% in Q2 2026, selling an estimated $560K and leaving 97,787 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #627.

Rafferty Asset Management first reported a position in SNDX in Q3 2020 and has held it in 24 quarters since. The position peaked at $8.88M in Q1 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Rafferty Asset Management held 97,787 shares of Syndax Pharmaceuticals worth $2.14M as of Q2 2026.
  • Rafferty Asset Management sold 26,936 Syndax Pharmaceuticals shares in Q2 2026, an estimated $560K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #627 holding.
  • Rafferty Asset Management first reported a position in Syndax Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Rafferty Asset Management's Syndax Pharmaceuticals position peaked at $8.88M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.